Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Millions of Americans will save on Medicare fees next year

For the first time in a decade, Americans will pay less next year on monthly premiums for Medicare’s Part B plan, which covers routine doctors’ visits and other outpatient care

The Independent UK

Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family

Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.

Benzinga

Atai's New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage

Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session

Gainers

Benzinga

Autumn Covid-19 vaccine roll-out to 'double your defences' ahead of uncertain winter

Vulnerable groups may have already been called to have their fourth Covid-19 jab

Chronicle Live

1 Stock Living up to Its Name This Year

Biopharmaceutical company Bristol Myers Squibb (BMY) reported stable revenue growth for the second quarter thanks to outstanding clinical and operational performance. Furthermore, despite generating significant momentum over the past few months, the stock is trading at a discounted valuation. So, we think it may be prudent to scoop its shares…

StockNews.com

Biogen pays $900M to settle doctor kickback allegations

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade them to prescribe its multiple sclerosis drugs

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Sell Before the End of This Year

The biotech industry witnessed solid growth during the pandemic. However, that seems to be fading away amid the receding pandemic and growing recession concerns. So, it could be wise to avoid biotech stocks Ginkgo Bioworks Holdings (DNA), GeoVax Labs (GOVX), and Aditxt (ADTX), given their bleak fundamentals. Read on….

StockNews.com

3 Stocks to Get Bullish on Right Now

Record-high inflation, the Federal Reserve's hawkish stance, and growing recession fears have increased market volatility. Nevertheless, despite the unsettling macroenvironment, few stocks have delivered stable returns and could continue to beat the market based on their solid growth attributes. AbbVie Inc. (ABBV), J. Jill Inc. (JILL), and Bassett Furniture Industries…

StockNews.com

Insider Q&A: FDA official on vaping's "promise or peril"

The new chief at the Food and Drug Administration's tobacco center has inherited a raft of problems

The Independent UK

Pfizer seeks to expand omicron booster to 5- to 11-year-olds

Pfizer is asking the Food and Drug Administration to expand use of its updated COVID-19 booster shot to children ages 5 to 11

The Independent UK

Commentary: Prevent a legal Catch-22 that could push thousands of generic drugs off the market

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back…

Los Angeles Times

Republican abortion bans restrict women’s access to other essential medicine

Many pharmacies and physicians are forced to deny patients access to drugs, such as methotrexate, that can be used to help induce an abortion

The Guardian - US

‘If not for the Ice Bucket Challenge, we wouldn’t be here’: Cambridge company on the brink of FDA-approved ALS treatment

BOSTON — Eight years after the ALS Ice Bucket Challenge went viral across social media and raised hundreds of millions of dollars for research, a Cambridge company is on the brink of a major breakthrough for ALS patients.

Boston Herald

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

HRT: inside the complex global supply chain behind a $20bn market

As demand for menopause drugs soars, we trace the oestrogen production line from Chinese soya bean fields to European pharmacy shelves

Axios

Moderna seeks emergency authorization for COVID booster for children

The application for children ages 6 months to under 6 years is expected to be completed later this year.

The Independent UK

Advocates seek more say in how opioid settlements are spent

As billions of dollars in opioid lawsuit settlements are starting to flow to governments, families and advocates impacted by the opioid crisis are pushing for a meaningful say in how the money will be used

StockNews.com

1 Biotech Stock That Has Fallen Hard in 2022

Biotech stock Timber Pharmaceuticals (TMBR) is down more than 70% year-to-date. Analysts expect it to keep reporting losses over the next two years. So, will it be wise to buy the stock now? Read on to learn our view….

Get all your
news in one place.

100's of premium titles.
One news app.

The National (Scotland)

Suspected drug deaths in first six months of year 22 per cent lower than last year

The number of suspected drug deaths in Scotland in the first six months of this year has dropped by 22 compared to last year.

Benzinga

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On?

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

StockNews.com

1 Stock Under $65 That You Shouldn't Ignore

Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should drive its growth in the coming quarters. Given GILD’s discounted valuation, we think it could be wise to buy this…

The Independent UK

FDA reminds people not to cook chicken in Nyquil after ‘dangerous’ social media trend resurfaces

‘These video challenges, which often target youths, can harm people — and even cause death,’ the agency said

The Independent UK

4.4M Americans roll up sleeves for omicron-targeted boosters

More than 4 million Americans have rolled up their sleeves for the new omicron-specific booster shots

Reuters

U.S. cutting global donations of Pfizer COVID shots as demand slows

The United States is significantly cutting back the number of Pfizer/BioNTech COVID-19 vaccine doses it will buy for donation to poorer nations this year, Pfizer said on Thursday, citing diminished demand for the shots in those countries.

Tribune News Service

Pfizer, US revise contract for donated vaccines as world demand plummets

WASHINGTON — President Joe Biden’s administration has slashed its target for COVID-19 vaccine donations abroad this year, amending a contract with Pfizer Inc. in the latest sign that world demand for the shots has collapsed.

1 … 129 130 131 132

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.